Press Release

BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders

Zurich-Schlieren, July 19, 2016. Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPins, was informed by Biotechnology Value Fund, L.P. and other entities affiliated with BVF Partners L.P. (BVF), a San Francisco-based investor focused on biotechnology, that it holds 4.58% of the voting rights and share capital of Molecular Partners. According to BVF’s declaration dated July 18, 2016 pursuant to Article 120 of the Swiss Financial Market Infrastructure Act, the 3% threshold was crossed on
July 18, 2016.

On July 18, 2016, Molecular Partners was also informed that Index Ventures and Essex Woodlands Health Ventures have fallen below the 15% threshold on the same day.

None of the founders or members of the management team sold any shares in this context.
Christian Zahnd, CEO of Molecular Partners commented: “We are very happy to see that we could gain more interest and support from BVF. We have extensive experience in working together with BVF; their skills and understanding of the long-term value perspective of Molecular Partners makes it a privilege to work with such a highly reputable group.”

Molecular Partners welcome this important step to further expand its long-term oriented specialist investor base.


Financial Calendar 2016

Publication of Half-year Results 2016

September 1, 2016

Publication of Quarterly Management Statement Q3 2016

October 27, 2016


About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to:

For further details, please contact:

Dr. Christian Zahnd, CEO
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Tel: +41 (0) 43 344 42 42



This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.